325 related articles for article (PubMed ID: 24064957)
1. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials.
Srivatsan S; Patel JM; Bozeman EN; Imasuen IE; He S; Daniels D; Selvaraj P
Hum Vaccin Immunother; 2014; 10(1):52-63. PubMed ID: 24064957
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.
Errington F; Bateman A; Kottke T; Thompson J; Harrington K; Merrick A; Hatfield P; Selby P; Vile R; Melcher A
Clin Cancer Res; 2006 Feb; 12(4):1333-41. PubMed ID: 16489091
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic breast cancer cell vaccines.
Dols A; Meijer SL; Smith JW; Fox BA; Urba WJ
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S173-80. PubMed ID: 12620156
[TBL] [Abstract][Full Text] [Related]
5.
James CA; Ronning P; Cullinan D; Cotto KC; Barnell EK; Campbell KM; Skidmore ZL; Sanford DE; Goedegebuure SP; Gillanders WE; Griffith OL; Hawkins WG; Griffith M
Cancer Res Commun; 2021 Nov; 1(2):115-126. PubMed ID: 35611186
[TBL] [Abstract][Full Text] [Related]
6. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
7. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
Schadendorf D; Paschen A; Sun Y
Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
[TBL] [Abstract][Full Text] [Related]
8. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
9. Single vs. combination immunotherapeutic strategies for glioma.
Chandran M; Candolfi M; Shah D; Mineharu Y; Yadav VN; Koschmann C; Asad AS; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2017 May; 17(5):543-554. PubMed ID: 28286975
[TBL] [Abstract][Full Text] [Related]
10. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
[TBL] [Abstract][Full Text] [Related]
11. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
12. Autologous versus allogeneic cell-based vaccines?
Parmiani G; Pilla L; Maccalli C; Russo V
Cancer J; 2011; 17(5):331-6. PubMed ID: 21952283
[TBL] [Abstract][Full Text] [Related]
13. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
14. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy: sipuleucel-T and beyond.
Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
[TBL] [Abstract][Full Text] [Related]
16. Characterization of polyvalent allogeneic vaccines.
Van Epps D
Dev Biol (Basel); 2004; 116():79-90; discussion 133-43. PubMed ID: 15603185
[TBL] [Abstract][Full Text] [Related]
17. Current status of immunotherapy for the treatment of biliary tract cancer.
Takahashi R; Yoshitomi M; Yutani S; Shirahama T; Noguchi M; Yamada A; Itoh K; Sasada T
Hum Vaccin Immunother; 2013 May; 9(5):1069-72. PubMed ID: 23376808
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell vaccines.
Thompson PL; Dessureault S
Adv Exp Med Biol; 2007; 601():345-55. PubMed ID: 17713023
[TBL] [Abstract][Full Text] [Related]
19. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
